INHBE and telangiectasis: Adverse events consistent with the drug’s activin-signalling mechanism—most notably epistaxis, telangiectasia, and dizziness—occurred more frequently in the sotatercept group than in the placebo group, in line with the expected on-target pharmacodynamic effects.